A Phase 4 interventional study of Amlodipine 5mg/Valsartan 80 mg and Valsartan in Hypertension and High Blood Pressure, sponsored by Novartis. Completed at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-19.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 146th largest by enrollment of the 186 interventional ones that give a count, is one of 13 that started in 2009, is one of 80 in phase 4, and was the 88th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 13 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 184th largest by enrollment of the 223 interventional ones that give a count, is one of 17 that started in 2009, is one of 67 in phase 4, and was the 181st registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to assess efficacy and safety of fixed dose combination of 5 mg amlodipine/80 mg valsartan compared to 160 mg valsartan monotherapy in lowering blood pressure in Taiwanese patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks.
Drug: Amlodipine 5mg/Valsartan 80 mg
In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks.
Drug: Valsartan
During run-in period, oral valsartan 80 mg once daily for 4 weeks.
Drug: Valsartan
Drug page: AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
Also known as: Exforge
For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks. Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks
Also known as: Diovan
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) From Office Blood Pressure Measurement
Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting systolic blood pressure (msSBP) was calculated comparing the Week 8 readings to the readings taken at baseline.
Time frame: Baseline and 8 weeks
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) From Office Blood Pressure Measurement
Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting diastolic blood pressure (msDBP) was calculated comparing the Week 8 readings to the readings taken at Baseline.
Time frame: Baseline and 8 weeks
Change From Baseline in Mean Systolic Blood Pressure (mSBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours
Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean systolic blood pressure (mSBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind phase.
Time frame: Baseline and 8 weeks
Change From Baseline in Mean Diastolic Blood Pressure (mDBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours After 8 Weeks of Treatment During the Double-blind Phase
Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean diastolic blood pressure (mDBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind.
Time frame: Baseline and 8 weeks
Number of Participants With Adverse Events During Double-blind Phase
Time frame: 8 weeks
| Milestone | Run-In Valsartan 80 mg | Amlodipine 5 mg/Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Started | 60 | 0 | 0 |
| Completed | 42 | 0 | 0 |
| Not completed | 18 | 0 | 0 |
| Withdrew: Did not meet inclusion criteria | 18 | 0 | 0 |
| Milestone | Run-In Valsartan 80 mg | Amlodipine 5 mg/Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|---|
| Started | 0 | 21 | 21 |
| Completed | 0 | 21 | 19 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 2 |
Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting systolic blood pressure (msSBP) was calculated comparing the Week 8 readings to the readings taken at baseline.
| mmHg | Amlodipine 5 mg/Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|
| Baseline | 150.26 ± 12.91 | 141.14 ± 12.71 |
| 8 weeks | 133.79 ± 14.63 | 133.68 ± 12.73 |
| Change from baseline to 8 weeks | -16.48 ± 15.53 | -7.23 ± 11.60 |
Two arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in mean sitting diastolic blood pressure (msDBP) was calculated comparing the Week 8 readings to the readings taken at Baseline.
| mmHg | Amlodipine 5 mg/Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|
| Baseline | 92.12 ± 10.84 | 89.98 ± 9.37 |
| 8 weeks | 82.29 ± 8.74 | 86.73 ± 9.10 |
| Change from baseline to 8 weeks | -9.83 ± 7.66 | -2.65 ± 6.75 |
Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean systolic blood pressure (mSBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind phase.
| mmHg | Amlodipine 5 mg/Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|
| Baseline | 144.38 ± 17.39 | 139.76 ± 13.46 |
| 8 weeks | 129.67 ± 14.03 | 131.11 ± 12.39 |
| Change from baseline to 8 weeks | -14.71 ± 11.64 | -6.39 ± 12.06 |
Validated automated ambulatory blood pressure monitors were dispensed to participants with instructions on correct use. Automated blood pressure readings were obtained every 15-30 minutes during waking hours and every 30-60 minutes during sleep for a total of 24 hours. The change in mean diastolic blood pressure (mDBP) over 24 hours was measured from baseline to 8 weeks of treatment during the double-blind.
| mmHg | Amlodipine 5 mg/Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|
| Baseline | 86.95 ± 14.14 | 87.90 ± 9.44 |
| 8 weeks | 79.29 ± 10.70 | 82.94 ± 8.42 |
| Change from baseline to 8 weeks | -7.67 ± 7.43 | -3.56 ± 7.70 |
| Participants | Amlodipine 5 mg/Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|
| Total AE | 9 | 15 |
| At least one AE | 7 | 11 |
| AE Not related to drug | 9 | 15 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amlodipine 5 mg/Valsartan 80 mg | — | 0/21 (0%) | 6/21 (28.6%) |
| Valsartan 160 mg | — | 1/21 (4.8%) | 8/21 (38.1%) |
| Event | Amlodipine 5 mg/Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/21 | 1/21 |
| Event | Amlodipine 5 mg/Valsartan 80 mg | Valsartan 160 mg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/21 | 3/21 |
| DizzinessNervous system disorders | 0/21 | 2/21 |
| HeadacheNervous system disorders | 2/21 | 1/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/21 | 2/21 |
| Age Continuous(years) | Amlodipine 5mg/Valsartan 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|
| Mean | 59.50 ± 13.81 | 55.13 ± 11.81 | 57.31 ± 13.81 |
| Sex: Female, Male(Participants) | Amlodipine 5mg/Valsartan 80 mg | Valsartan 160 mg | Total |
|---|---|---|---|
| Female | 9 | 8 | 17 |
| Male | 12 | 13 | 25 |
The record gives a start of Jun 2009, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine